跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 19,652 条关于
“anti-AchR”
全部
19,652
临床试验
9,932
药物
3,776
机构
82
资讯
5,862
10个月前
Johnson & Johnson Launches First Head-to-Head FcRn Blocker Study in Myasthenia Gravis
去年
Myasthenia Gravis Market Set to Reach $10.3 Billion by 2034 Driven by Seven Late-Stage Pipeline Therapies
去年
Nipocalimab Receives FDA Priority Review for Generalized Myasthenia Gravis Treatment
去年
FDA Approves Soliris for Refractory Myasthenia Gravis, First New Treatment in 60 Years
2年前
Nipocalimab Shows Sustained Disease Control in Adolescents with Generalized Myasthenia Gravis
去年
Eculizumab Shows Promise in Treating Thymoma-Associated Myasthenia Gravis
去年
Zilbrysq Market Projected to Grow 21.64% Annually Through 2030 Following FDA Approval for Myasthenia Gravis
去年
Ultomiris Shows Delayed but Significant Benefit in Generalized Myasthenia Gravis
去年
NMD Pharma Presents Preclinical Data on ClC-1 Ion Channel Inhibition for MuSK Myasthenia Gravis Treatment
9个月前
FDA Approves UPLIZNA as First CD19-Targeted B Cell Therapy for Generalized Myasthenia Gravis
第 1 页,共 587 页
上一页
下一页